Navigation Links
Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX

- ViziLite Plus with TBlue630 -

PHOENIX, Sept. 4 /PRNewswire-FirstCall/ -- Zila, Inc.'s (Nasdaq: ZILA) ViziLite(R) Plus with Tblue630(TM) screening system for early detection of abnormalities which can lead to oral cancer, has been selected to identify pre-cancerous lesions in a Phase II study of Cetuximab (ERBITUX(R)), a leading cancer therapeutic for head and neck cancer developed by ImClone Systems (Nasdaq: IMCL) and distributed by Bristol-Meyers Squibb (NYSE: BMY).

The NIH has awarded a Specialized Program of Research Excellence (SPORE) grant for the study. The primary objective of the clinical trial is to evaluate ERBITUX efficacy in treating upper aerodigestive pre-cancer. ERBITUX is currently marketed for the treatment of head and neck cancer (including upper aerodigestive) as well as metastatic colorectal cancer.

Dr. Frank J.Bellizzi, President of Zila Pharmaceuticals, "We are pleased that Zila's ViziLite Plus with Tblue630 has been selected for use in this clinical trial. The use of ViziLite Plus in such an important study with the leading head and neck cancer therapeutic demonstrates its growing reputation as the premier oral cancer screening technology."

The coordinating center for the study is The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. The Protocol Chairman is Joseph Califano, M.D., of the Department of Otolaryngology-Head and Neck Surgery.

Over 30 clinical investigators at key academic research institutions and cancer research centers are scheduled to participate in the study. The Phase II study is anticipated to enroll and evaluate approximately 60 patients over a three-year period. Patients will be evaluated clinically and biopsies will be taken pre- and post-treatment. The biopsies will be analyzed histopathologically, but will also be analyzed for genetic changes using Zila's proprietary LOH assay. The assay is the only validated method for identifying biomarkers consistent with oral premalignencies and oral cancer.

About ViziLite(R) Plus

ViziLite(R) Plus is an oral screening technology that utilizes ViziLite, an advanced chemiluminescent light technology, with Tblue630. The Tblue630 marking system employs Zila Tolonium Chloride (ZTC(TM)), the only patented pharmaceutical-grade form of toluidine blue in an FDA-cleared device.

For more information about ViziLite Plus, visit

About Zila's LOH Assay

Biopsies are traditionally analyzed histopathologically to determine the histological changes in diseased tissue and enable classification of the tissue such as benign, dysplastic or cancerous. Leading cancer centers now recognize the value of also evaluating the DNA of biopsy samples for markers that signal that tissue is on the progression pathway to cancer. Zila has developed a proprietary DNA assay that evaluates chromosomal deletions by determining the loss of heterozygosity (LOH) of such biopsies. The validated LOH assay is utilized in the Zila OraTest Phase III clinical trial as well as the Erbitux Study, and the Company is evaluating commercial opportunities for the test.

About Zila, Inc.

Zila, Inc., headquartered in Phoenix, is an oral cancer screening company focused on the prevention and treatment of oral disease. Zila is dedicated to establishing ViziLite(R) Plus as the new standard of care for the early detection of oral abnormalities that could lead to cancer, with an initial focus on the dental market through Pro-Dentec(R), a leading designer, manufacturer and marketer of Soft Tissue Management (STM(R)) products. Sold exclusively and directly to dental professionals, Pro-Dentec's core products include the Rota-dent(R) Professional Powered Brush, the Pro-Select3(R) Piezo-Ultrasonic Scaler System and a suite of pharmaceutical STM(R) products for both in-office and home-care use.

For more information about Zila, visit

SOURCE Zila, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
5. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
8. PromegaExpress Expands Easy Access to Products with New Cabinet
9. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
10. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
11. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
Post Your Comments:
(Date:12/1/2015)... ) has ... Systems/Personal Emergency Response System (PERS) Market by Type, ... report to their offering. --> ... "Medical Alert Systems/Personal Emergency Response System (PERS) ... - Global Forecas" report to their offering. ...
(Date:12/1/2015)... THE WOODLANDS, Texas , Dec. 1, ... LXRX )  announced today that top-line data ... results of telotristat etiprate in treating carcinoid ... tumors consistent with the clinical benefit observed ... study was designed as a companion to ...
(Date:12/1/2015)... -- North America orthobiologics ... and forecast of revenue. --> North ... concerned market with analysis and forecast of revenue. ... American Orthobiologics Market by Type (Bone Allograft, Bone Graft ... Therapy, Viscosupplementation), by End-User (Hospitals, Point-of-Care Testing) - Analysis ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and medical ... the devices for sale in the United States. Clarity is a Superior Dual ... Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech North ... Gary has spent a significant amount of time in Sweden since joining PartnerTech ...
(Date:12/1/2015)... ... December 01, 2015 , ... SonaCare Medical congratulates the University ... Innovation Award on November 18th. This prestigious award recognizes annually organizations that cultivate ... to the medical landscape. , The UCLH team won the award for their ...
(Date:11/30/2015)... ... , ... Trevor and Taylor Crabb have unveiled an exciting new campaign ... the United States. This hybrid crowdfunding campaign is designed to provide the ... addition to offering corporate sponsors with some great marketing deliverables with the brothers for ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, ... ... (NAPW) honors Dale Jones as a 2015-2016 inductee into its ... for leadership in education. NAPW is the nation’s leading networking organization exclusively for ...
Breaking Medicine News(10 mins):